36 reports of this reaction
2.3% of all PROPARACAINE HYDROCHLORIDE reports
#9 most reported adverse reaction
ULCERATIVE KERATITIS is the #9 most commonly reported adverse reaction for PROPARACAINE HYDROCHLORIDE, manufactured by Alcon Laboratories, Inc.. There are 36 FDA adverse event reports linking PROPARACAINE HYDROCHLORIDE to ULCERATIVE KERATITIS. This represents approximately 2.3% of all 1,545 adverse event reports for this drug.
Patients taking PROPARACAINE HYDROCHLORIDE who experience ulcerative keratitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ULCERATIVE KERATITIS is a less commonly reported adverse event for PROPARACAINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to ulcerative keratitis, the following adverse reactions have been reported for PROPARACAINE HYDROCHLORIDE:
ULCERATIVE KERATITIS has been reported as an adverse event in 36 FDA reports for PROPARACAINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ULCERATIVE KERATITIS accounts for approximately 2.3% of all adverse event reports for PROPARACAINE HYDROCHLORIDE, making it a notable side effect.
If you experience ulcerative keratitis while taking PROPARACAINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.